When: Price stabilization at $135-143 with RSI reset toward 55-60

Then: Add back to core position

REDUCE/TRIM: reduce approximately 25% now, additional 10-15% tranche if MRK rallies to $152-$154, retain at least 50% core, avoid naked short and stop orders attached to completed trim; use protective puts or collar for hedging

• MRK has risen roughly 25% in six weeks with RSI cooling from 83 to 73.7
• Price closed at $150.66, above 10-day EMA ($143.01), 50-day SMA ($128.58), and 200-day SMA ($114.57)
• MACD is positive at 5.98 versus signal line at 3.96 with histogram expanding at 2.03
• ATR has risen to $4.34, indicating higher volatility in both directions
• Net debt has risen from approximately $18 billion to $47 billion
• Forward P/E of 15.8x on $9.54 EPS is consistent with $151 price, not excessive
• Gross margins generally in 73% to 78% range with approximately $15.17 billion trailing free cash flow
• Current ratio of 1.32 and established dividend provide adequate liquidity
• Proposed $154.50 stop is less than one ATR and vulnerable to ordinary price movement
• Sell limit at $152 may never fill if MRK moves toward $143 to $135 support
• $4.3 billion market-cap addition represents only about 1.2% of $371.7 billion market cap
• Sentiment score of 7.2 out of 10 with medium confidence and limited retail discussion
• H1 2026 operating losses affected by acquisition-related R&D and IPR&D charges, not underlying business collapse
• A close below 10-day EMA near $143 with weak volume is reason to reassess core
• Break below $135 would be serious deterioration; do not average down until stabilization
• Daily close above $154.50 on >20 million shares would invalidate bearish thesis

→ vs aggressive: SELL is not a near-zero-risk, asymmetric trade; the $154.50 stop is less than one ATR and vulnerable to ordinary price movement

→ vs aggressive: The risks justify a smaller position but do not prove a large short has favorable expected value

→ vs aggressive: ATR and Bollinger arguments do not establish a short; higher volatility means greater risk in both directions

→ vs aggressive: Trade structure is internally inconsistent: a trim does not require a stop on the sold tranche, but attaching $154.50 stop to residual position could sell into strength and unintentionally reverse into an unhedged short

→ vs aggressive: Valuation at forward P/E 15.8x is not a convincing short thesis; forward P/E of 15.8 on $9.54 EPS is consistent with price near $151

→ vs aggressive: $4.3 billion market-cap addition is only ~1.2% of $371.7 billion market cap and is market repricing, not an asset that must disappear

→ vs aggressive: Institutional-led move may be less crowded and more durable; sentiment report gives 7.2 bullish score with medium confidence and limited retail discussion

→ vs neutral: Waiting for ESMO has opportunity cost and event risk; holding full position without a defined exposure limit is too passive

→ vs neutral: Strong fundamentals should not justify ignoring concentration and catalyst risk; neutral position becomes unsafe when treating fundamentals as reason to skip exposure limits

SELL 25-40% of MRK exposure at or near current prices ($150-152) with an optional rally tranche at $152-154; retain core position of 50%+ sized for new volatility regime; use $143 (10-day EMA) as tactical invalidation rather than $154.50; avoid creating naked short exposure from ambiguous stop structure.

• Execute 25% base trim now at current prices ($150-152), not contingent on $152-154 fill
• Stage optional 10-15% additional tranche as sell limit into $152-154 if maximizing exit price
• Retain minimum 50% core position as intomerasan plus Keytruda is a real fundamental win
• Use daily close below 10-day EMA at $143 on weak volume as invalidation for residual core, not $154.50
• ATR has doubled to $4.34 from $2.6; position sizing should be halved to maintain equivalent dollar volatility
• Re-entry zones: $135-143 on ESMO disappointment pullback with volume stabilization; above $154.50 on strength for adding back
• Dividend yield of 2.23% insufficient to justify full event exposure when money market funds yield 4%+
• MRK is $370B market cap defensive compounder (0.21 beta) not a momentum name; post-catalyst consolidation is normal
• Avoid ambiguous stop structure that could create naked short if sold tranche triggers $154.50 stop on continued upside
• RSI rolled over from 83 to 73.7 with bearish divergence; Aug 21 high of $154.49 followed by 2.5% pullback on declining volume

→ vs aggressive: Three errors in 'risk-free' framing: (1) $2.50 stop is less than one ATR of $4.34 so intraday movement can trigger it prematurely; (2) gap risk in healthcare catalysts post-12.6% gap is real; (3) stop attached to sold tranche is structurally incoherent—residual position should use $143 invalidation, not $154.50 stop

→ vs aggressive: Downside framing is too binary; $4.3B premium reflects Phase 3 topline win, not ESMO detail—if ESMO disappoints, expect 5-10% pullback, not 20%, because market already priced positive read into the move

→ vs aggressive: Institutional fragility argument contradicts itself; thin retail with institutional sponsorship can indicate durable professional bid, not fragile momentum flow—the sentiment report says confidence is medium because retail is thin, not because move is suspect

→ vs conservative: Treating trim recommendation as optional or cosmetic is wrong; technical setup (RSI rollover, bearish divergence, post-breakout consolidation with declining volume) means event-risk exposure is at maximum and trim is structural necessity

→ vs conservative: Suggestion to stage trim near $150-152 'concedes the aggressive argument'—if trimming at current prices, disagreement is only about waiting for fills versus executing now, and waiting risks gap-down on binary event to $145 or worse

→ vs conservative: Carrying full event exposure has real cost: 6 weeks of opportunity cost while MRK ranges $143-155, collecting $0.42 dividend per share versus 4%+ in money markets, exposed to every biotech tape day and MRNA volatility

→ vs conservative: Fundamentals provide a price floor but don't dictate tactical timing; treating dividend and FCF as reason to ignore near-term technical and event risk is mirror image of aggressive analyst's momentum error